$BYSI News

Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical Benefit

BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY

BeyondSpring Q4 EPS $(0.05)

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

BeyondSpring Announces Asian Subset Results From Phase 3 DUBLIN-3 Trial Of Plinabulin In EGFR Wild-Type NSCLC At ESMO Asia 2025

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

BeyondSpring Announces New Post-Hoc Analyses From Global Phase 3 DUBLIN-3 Study, Showing Plinabulin Plus Docetaxel Provides Clinically Meaningful Benefit For Patients With EGFR WT NSQ NSCLC

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

BeyondSpring Q3 EPS $(0.04) Up From $(0.05) YoY

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

BeyondSpring Q2 EPS $(0.04) Up From $(0.10) YoY

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BeyondSpring Drug Triggers Immune Response in Patients Who Failed Prior Cancer Immunotherapy

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

BeyondSpring Presents Interim Phase 2 Data On 303 Study With Financial Support From Merck's Investigator Studies Program And Provision Of Study Drug, At 2025 ASCO Annual Meeting

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?